<HashMap><database>biostudies-literature</database><scores><citationCount>0</citationCount><reanalysisCount>0</reanalysisCount><viewCount>271</viewCount><searchCount>0</searchCount></scores><additional><submitter>Ye L</submitter><funding>NIDA NIH HHS</funding><funding>NCI NIH HHS</funding><funding>U.S. Department of Health &amp;amp; Human Services | National Institutes of Health</funding><funding>NIH HHS</funding><funding>NIGMS NIH HHS</funding><pagination>1302-1313</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6834896</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>37(11)</volume><pubmed_abstract>Targeting membrane proteins could improve the efficacy of T cell-based immunotherapies. To facilitate the identification of T cell targets, we developed a hybrid genetic screening system where the Sleeping Beauty (SB) transposon and single guide RNA cassette are nested in an adeno-associated virus (AAV). SB-mediated genomic integration of the single guide RNA cassette enables efficient gene editing in primary murine T cells as well as a screen readout. We performed in vivo AAV-SB-CRISPR screens for membrane protein targets in CD8&lt;sup>+&lt;/sup> T cells in mouse models of glioblastoma (GBM). We validated screen hits by demonstrating that adoptive transfer of CD8&lt;sup>+&lt;/sup> T cells with Pdia3, Mgat5, Emp1 or Lag3 gene editing enhances the survival of GBM-bearing mice in both syngeneic and T-cell receptor transgenic models. Transcriptome profiling, single cell sequencing, cytokine assays and T cell signaling analysis showed that Pdia3 editing in T cells enhances effector functions. Engineered PDIA3 mutant EGFRvIII chimeric antigen T cells are more potent in antigen-specific killing of human GBM cells.</pubmed_abstract><journal>Nature biotechnology</journal><pubmed_title>In vivo CRISPR screening in CD8 T cells with AAV-Sleeping Beauty hybrid vectors identifies membrane targets for improving immunotherapy for glioblastoma.</pubmed_title><pmcid>PMC6834896</pmcid><funding_grant_id>U54 CA209992</funding_grant_id><funding_grant_id>DP2 CA238295</funding_grant_id><funding_grant_id>RF1 DA048811</funding_grant_id><funding_grant_id>1R33CA225498</funding_grant_id><funding_grant_id>1U54CA209992-8697</funding_grant_id><funding_grant_id>T32 GM007205</funding_grant_id><funding_grant_id>S10 OD018521</funding_grant_id><funding_grant_id>R01 CA231112</funding_grant_id><funding_grant_id>1R01CA231112</funding_grant_id><funding_grant_id>R33 CA225498</funding_grant_id><pubmed_authors>Ye L</pubmed_authors><pubmed_authors>Guo J</pubmed_authors><pubmed_authors>Park JJ</pubmed_authors><pubmed_authors>Errami Y</pubmed_authors><pubmed_authors>Chow RD</pubmed_authors><pubmed_authors>Du Y</pubmed_authors><pubmed_authors>Wang G</pubmed_authors><pubmed_authors>Yang Q</pubmed_authors><pubmed_authors>Peng L</pubmed_authors><pubmed_authors>Chen S</pubmed_authors><pubmed_authors>Dong MB</pubmed_authors><pubmed_authors>Dai X</pubmed_authors><view_count>271</view_count></additional><is_claimable>false</is_claimable><name>In vivo CRISPR screening in CD8 T cells with AAV-Sleeping Beauty hybrid vectors identifies membrane targets for improving immunotherapy for glioblastoma.</name><description>Targeting membrane proteins could improve the efficacy of T cell-based immunotherapies. To facilitate the identification of T cell targets, we developed a hybrid genetic screening system where the Sleeping Beauty (SB) transposon and single guide RNA cassette are nested in an adeno-associated virus (AAV). SB-mediated genomic integration of the single guide RNA cassette enables efficient gene editing in primary murine T cells as well as a screen readout. We performed in vivo AAV-SB-CRISPR screens for membrane protein targets in CD8&lt;sup>+&lt;/sup> T cells in mouse models of glioblastoma (GBM). We validated screen hits by demonstrating that adoptive transfer of CD8&lt;sup>+&lt;/sup> T cells with Pdia3, Mgat5, Emp1 or Lag3 gene editing enhances the survival of GBM-bearing mice in both syngeneic and T-cell receptor transgenic models. Transcriptome profiling, single cell sequencing, cytokine assays and T cell signaling analysis showed that Pdia3 editing in T cells enhances effector functions. Engineered PDIA3 mutant EGFRvIII chimeric antigen T cells are more potent in antigen-specific killing of human GBM cells.</description><dates><release>2019-01-01T00:00:00Z</release><publication>2019 Nov</publication><modification>2024-11-12T00:05:12.442Z</modification><creation>2020-05-22T13:50:22Z</creation></dates><accession>S-EPMC6834896</accession><cross_references><pubmed>31548728</pubmed><doi>10.1038/s41587-019-0246-4</doi></cross_references></HashMap>